Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Change in Taxes (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Change in Taxes for 8 consecutive years, with -$1.9 million as the latest value for Q2 2025.

  • Quarterly Change in Taxes fell 179.44% to -$1.9 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was -$2.7 million through Dec 2025, down 200.0% year-over-year, with the annual reading at -$2.7 million for FY2025, 200.0% down from the prior year.
  • Change in Taxes hit -$1.9 million in Q2 2025 for Protagonist Therapeutics, down from -$800000.0 in the prior quarter.
  • In the past five years, Change in Taxes ranged from a high of $3.3 million in Q1 2024 to a low of -$1.9 million in Q2 2025.
  • Historically, Change in Taxes has averaged $164363.6 across 4 years, with a median of $33000.0 in 2022.
  • Biggest five-year swings in Change in Taxes: soared 363.58% in 2021 and later crashed 179.44% in 2025.
  • Year by year, Change in Taxes stood at $921000.0 in 2021, then crashed by 96.42% to $33000.0 in 2022, then skyrocketed by 4869.7% to $1.6 million in 2024, then plummeted by 215.18% to -$1.9 million in 2025.
  • Business Quant data shows Change in Taxes for PTGX at -$1.9 million in Q2 2025, -$800000.0 in Q1 2025, and $1.6 million in Q4 2024.